Novavax
FDA Approves Novavax COVID Vaccine After Delay, Limits Use to Smaller High-Risk Population
Novavax; FDA approval; COVID-19 vaccine; Nuvaxovid; restricted population; protein-based vaccine; older adults; underlying health conditions
Novavax’s COVID-19 jab looks to be on track for approval
Vaccines, COVID19 (disease), United States Food and Drug Administration, Approved, Novavax, Novavax ‘s, Novavax
FDA official said to step in and pause review of Novavax’s COVID-19 vaccine
United States Food and Drug Administration, COVID19 (disease), Vaccines, Novavax ‘s, Review [Publication Type], Novavax, Approved
Novavax Sells Czech Manufacturing Facility to Novo Nordisk for $200 Million
Novavax, Novo Nordisk, Czech manufacturing facility, cost-cutting, vaccine pipeline development
Coherus Resumes Biosimilar Supply Following Temporary Disruption; Novavax Terminates COVID-19 Vaccine Deal with UK
Coherus BioSciences, Biosimilar supply, UDENYCA, Supply chain issues, Novavax, COVID-19 vaccine deal, UK
FDA Places Clinical Hold on Novavax’s COVID-19-Influenza Combination and Stand-Alone Influenza Vaccine Candidates Due to Rare Adverse Event
Novavax, FDA, COVID-19, Influenza, Vaccine, Clinical Hold, Motor Neuropathy
FDA Places Clinical Hold on Novavax’s COVID-19-Influenza Combination and Standalone Influenza Vaccine Trials
Novavax, FDA, Clinical Hold, COVID-19, Influenza, Vaccine Trials, Motor Neuropathy
FDA Authorizes Novavax’s Updated COVID-19 Vaccine for Emergency Use
Novavax COVID-19 Vaccine, FDA Authorization, Emergency Use, Protein-Based Vaccine, JN.1 Variant
Novavax’s Updated COVID-19 Vaccine Receives FDA Emergency Use Authorization
Novavax, COVID-19 vaccine, FDA, Emergency Use Authorization, protein-based vaccine, JN.1 variant
Sanofi Invests $500M in Novavax’s Covid Vaccine, Exploring Commercialization and Flu Combination
Sanofi, Novavax, Covid vaccine, commercialization, flu combination, $500M investment